Before everyone gives up, I think we need to sort
Post# of 30028
Posted On: 07/31/2014 4:57:18 PM
Before everyone gives up, I think we need to sort through things a bit. The whole LymPro Testing process has been communicated to us very poorly. I think the purchase of LymPro version 2 changed their game plan and when they did certain tests.
Gerald told me in Santa Monica 3 months ago that they would be doing a "large test" in Q2 (150 to 200 patient range) The reason why I was upset after Copenhagen is that I was expecting to hear the results of that larger test. But we didn't get it. Instead, we were told we'd get the "top line" results of a "bridge test" comparing version 2 with version 1. We got that today, but only a portion of it, 44 patients and only 10 with AD. The results given 70 & 80 percent were not impressive because the sample group was too small.
Obviously, AMBS decided to go with version 2 and that has put them behind in their testing. I suspect version 2 will give them the superior numbers in the mid 90s once enough patients are tested. In Gerald's blog after Copenhagen he said that the "larger test" will be done once we are in the lab of our CLIA partner.
As I said after Copenhagen, AMBS suffers when it comes to communication. But I don't think Beckton Dickenson's validation is bogus. Nor do I discount all the prominent diagnostic people that have come on board to launch LYmPro. LymPro isn't a scam, it is simply behind schedule.
Why did Gerald build up these two Conferences when the data was not ready? He must explain that. We've paid a heavy price. But I suspect our pps will pop back up very quickly once they get caught up with their testing. That may take awhile. AMBS is still a very promising company in my opinion, but they've experienced some growing pains.
Gerald still hasn't spoken at the Conference yet as I finish this post. Perhaps he will turn things around? I hope so.
Gerald told me in Santa Monica 3 months ago that they would be doing a "large test" in Q2 (150 to 200 patient range) The reason why I was upset after Copenhagen is that I was expecting to hear the results of that larger test. But we didn't get it. Instead, we were told we'd get the "top line" results of a "bridge test" comparing version 2 with version 1. We got that today, but only a portion of it, 44 patients and only 10 with AD. The results given 70 & 80 percent were not impressive because the sample group was too small.
Obviously, AMBS decided to go with version 2 and that has put them behind in their testing. I suspect version 2 will give them the superior numbers in the mid 90s once enough patients are tested. In Gerald's blog after Copenhagen he said that the "larger test" will be done once we are in the lab of our CLIA partner.
As I said after Copenhagen, AMBS suffers when it comes to communication. But I don't think Beckton Dickenson's validation is bogus. Nor do I discount all the prominent diagnostic people that have come on board to launch LYmPro. LymPro isn't a scam, it is simply behind schedule.
Why did Gerald build up these two Conferences when the data was not ready? He must explain that. We've paid a heavy price. But I suspect our pps will pop back up very quickly once they get caught up with their testing. That may take awhile. AMBS is still a very promising company in my opinion, but they've experienced some growing pains.
Gerald still hasn't spoken at the Conference yet as I finish this post. Perhaps he will turn things around? I hope so.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼